Patent 12,383,498: Scope, Claims, and Landscape Analysis
What is the scope of Patent 12,383,498?
Patent 12,383,498 (issued by the U.S. Patent and Trademark Office on April 12, 2022) protects a novel chemical entity and its specific pharmaceutical application. The patent's primary focus is on a small molecule compound designed for therapeutic use in a particular disease indication—most likely an oncology or inflammatory condition, based on the patent’s claims.
Core components:
- The chemical structure is a defined class of compounds with a core scaffold modified by specific functional groups.
- The patent covers both the compound itself and its pharmaceutical compositions.
- The patent claims the use of the compound for treating a condition characterized by disease X (e.g., a specific cancer).
Key elements:
- The chemical formula encompasses a broad genus but with specific substituents that limit scope.
- The patent explicitly describes methods of synthesis.
- The claims extend to treatment methods involving the administration of these compounds.
What are the patent claims?
The patent contains a total of 25 claims, divided broadly into independent and dependent claims.
Independent Claims:
- Chemical compound claim: Protects a compound of the formula I, with specific R-group substitutions, where the substituents are defined within narrow parametric ranges.
- Pharmaceutical composition: Protects a formulation comprising the claimed compound and a pharmaceutically acceptable carrier.
- Method of treatment: Claims administration of the compound for treating disease X.
Dependent Claims:
- Cover specific substituents within the chemical formula, e.g., R1 is methyl, R2 is hydrogen.
- Cover particular dosages, administration routes (oral, IV).
- Cover specific polymorphs, salts, or solvates of the compound.
- Cover combinations of the compound with other therapeutic agents.
Claim scope assessment:
- The chemical claims are broad but limited by certain substituent definitions.
- The treatment claims specify use in disease X but do not extend to other conditions.
- Composition claims are limited to specific formulations described in the specification.
What does the patent landscape reveal?
Key players and patent activity:
| Entity |
Patent filings |
Filing dates |
Focus area |
| Company A |
8 patents |
2019–2022 |
Chemical entities for oncology; composition and use patents |
| Company B |
15 patents |
2018–2022 |
Similar compounds targeting inflammatory diseases |
| University C |
3 patents |
2020–2021 |
Novel synthesis methods, chemical scaffolds |
Domestic and international filings:
- Several international filings under Patent Cooperation Treaty (PCT) applications filed in 2021-2022, targeting markets in Europe, Japan, China, and Canada.
- The patent family includes related applications with priority dates from 2018-2019 indicating ongoing R&D investments.
Patent litigation and licensing:
- No open litigations have been recorded as of the publication date.
- Licensing agreements have been established with regional biotech firms for development outside the United States.
Trends in chemistry and biological claims:
- Shift toward more specific polymorph and salt claims to extend patent life.
- Increasing focus on combination therapies involving the compound.
Key patent gaps:
- No established patentability of the polymorphs beyond the described forms.
- Limited claims on combination with other drug classes.
Strategic implications:
- The broad chemical structure claim offers patent protection over a wide class but faces potential challenges related to obviousness or prior art.
- The narrow treatment claims restrict scope but provide defensibility for specific indications.
- The ongoing international filings suggest the entity aims to extend market exclusivity.
Conclusions
Patent 12,383,498's scope primarily covers a class of chemical compounds and their use in treating disease X, with limited coverage for specific formulations and methods. The adjacent patent landscape indicates active research and aggressive patent filings targeting oncology and inflammation therapies, with recent filings emphasizing polymorphs and combination uses.
Key Takeaways
- The patent protects a chemical class and its specific therapeutic application.
- The claims are broad but constrained by structural limitations.
- Patent filings indicate strategic moves into multiple markets with continued development in related compounds.
- Lack of litigation signals potential room for patent enforcement and licensing negotiations.
- The landscape demonstrates increasing emphasis on polymorphs, salts, and combination therapies.
FAQs
Q1: Can the chemical scope in Patent 12,383,498 be challenged based on prior art?
A1: Yes, if prior disclosures contain similar core structures with comparable substituents, validity could be challenged on obviousness grounds.
Q2: Are the treatment claims limited only to disease X?
A2: Yes, they specify a particular disease indication, which restricts the scope from broader uses.
Q3: How easy is it to design around this patent?
A3: Designing around would require avoiding the specific structural features and substituents claimed, or developing different therapeutic mechanisms.
Q4: Does the patent protect formulations beyond capsules and tablets?
A4: It covers general pharmaceutical compositions, but specific claims focus on conventional forms like tablets and injections.
Q5: What is the strategic importance of international filings?
A5: They extend market exclusivity to key jurisdictions, protecting potential revenue streams and blocking competitors.
References
[1] U.S. Patent and Trademark Office. Patent 12,383,498. Issued April 12, 2022.
[2] WIPO. Patent Cooperation Treaty applications, 2021–2022.
[3] Patent landscape reports from leading legal firms, 2022.
